18th International Conference for the Society for Medical Innovation and Technology (SMIT 2006)

May 10th, 2006May 13th, 2006
Monterey, CA
US
https://www.smit2006.com
Latest in Home
Asco Thumb
ASCO: Use of GLP-1 drugs linked to lower breast cancer cases
June 2, 2026
A 68Ga-RCC78 PET scan (C) of a patient four years post-radical right nephrectomy. During follow-up, new nodules were detected in the left adrenal gland and kidney. CAIX-targeted scan clearly visualized metastatic lesions in the mediastinum, pancreas, adrenal gland, and kidney (SUVmax > 30), demonstrating the tracer's ability to maintain high tumor uptake despite significantly reduced abdominal background.
SNMMI: CAIX-targeted PET tracer detects clear cell renal cell carcinoma
June 1, 2026
Snmmi Thumb
SNMMI: Low-cost absorbents clear over 90% of Lu-177 from wastewater
June 1, 2026
(Left) F-18 GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg (from the thigh to the calf), as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image. (Right) 18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs (A), the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head (B), spine (C), heart (D), and pelvis (E). Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.
SNMMI: PET tracer that detects deep vein thrombosis wins Image of the Year
June 1, 2026
More in Home
ASCO: Use of GLP-1 drugs linked to lower breast cancer cases
By Erik L. Ridley
A large retrospective study found sharply lower incidence of breast cancer among women who had received GLP-1 drugs.
June 2, 2026
Asco Thumb
SNMMI: CAIX-targeted PET tracer detects clear cell renal cell carcinoma
By Liz Carey
Researchers aim for "more precise molecular map" for kidney cancer.
June 1, 2026
A 68Ga-RCC78 PET scan (C) of a patient four years post-radical right nephrectomy. During follow-up, new nodules were detected in the left adrenal gland and kidney. CAIX-targeted scan clearly visualized metastatic lesions in the mediastinum, pancreas, adrenal gland, and kidney (SUVmax > 30), demonstrating the tracer's ability to maintain high tumor uptake despite significantly reduced abdominal background.
SNMMI: Low-cost absorbents clear over 90% of Lu-177 from wastewater
By Kate Madden Yee
An increase in the use of radionuclide therapy has added burden to wastewater management systems.
June 1, 2026
Snmmi Thumb
SNMMI: PET tracer that detects deep vein thrombosis wins Image of the Year
By Will Morton
F-18 GP1 is derived from elarofiban and selectively binds to glycoprotein IIb/IIIa receptors on activated platelets.
June 1, 2026
(Left) F-18 GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg (from the thigh to the calf), as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image. (Right) 18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs (A), the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head (B), spine (C), heart (D), and pelvis (E). Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.
SNMMI: Novel radiotracer effectively images overactive adrenal glands
By Liz Carey
University of Michigan researchers report on first-in-human study of SOAT1-targeted nevanimibe C-11.
June 1, 2026
Static PET-CT image of patient with hypercortisolism taken at 60 minutes post-injection.
SNMMI: Mouaz Al-Mallah discusses cardiac PET
By Will Morton
In this interview, Mouaz Al-Mallah, MD, discusses cardiac PET imaging, including new efforts to create more access for patients and the impact of new radiotracers.
June 1, 2026
Mouaz Al Mallah Thumb1
ASCO: Proton therapy, IMRT both work well for prostate cancer
By Erik L. Ridley
Both modalities yielded similar outcomes, according to preliminary results from a large, prospective trial.
June 1, 2026
Asco Thumb
SNMMI: Point-of-care PET system may guide interventional procedures
By Amerigo Allegretto
A portable, point-of-care PET system showed success in imaging organs and may be helpful in interventional guidance.
June 1, 2026
(a) Benchtop portable POC-PET prototype system. (b) Phantom imaging experiment setup. (c) Comparison of conventional full-data MLEM reconstruction with incremental OSEM reconstruction.
SNMMI: Brain-dedicated PET scanner cuts claustrophobia, boosts comfort
By Kate Madden Yee
The findings "support the use of brain-dedicated PET scanners as a patient-centered alternative," researchers wrote.
June 1, 2026
Snmmi Thumb
SNMMI: PET tracer detects CTE tau pathology in living patients
By Kate Madden Yee
Study findings suggest "a clinical role for PET in traumatic brain injury and sports- and military-related neurodegeneration."
May 31, 2026
Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.
SNMMI: SPECT/CT tracer shows promise in interstitial lung disease
By Will Morton
Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.
May 31, 2026
Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.
SNMMI: Alpha-emitting tracer offers neuroendocrine tumor treatment option
By Kate Madden Yee
An alpha-emitting radiotracer produced remission in patients who had exhausted typical treatment options for neuroendocrine tumors.
May 31, 2026
Picture3
Page 1 of 230
Next Page